Tela Bio Inc (TELA)

2026-08-10T20:45:32.000Z - 8 days ago

Tela Bio reports Q2 EPS (20c), consensus (18c)

2026-08-10T20:45:28.000Z - 8 days ago

Tela Bio withdraws FY26 guidance

Aug 10, 2026, 4:30 PM EDT - 8 days ago

TELA Bio Earnings Call Transcript: Q2 2026

Aug 10, 2026, 4:30 PM EDT - 8 days ago

TELA Bio Earnings release: Q2 2026

Aug 10, 2026, 4:30 PM EDT - 8 days ago

TELA Bio Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 13 days ago

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-04T13:21:41.000Z - 14 days ago

Tela Bio appoints Heather Getz as CEO

BFLY

Aug 4, 2026, 7:00 AM EDT - 15 days ago

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

Jul 29, 2026, 4:05 PM EDT - 20 days ago

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Jul 20, 2026, 4:05 PM EDT - 4 weeks ago

TELA Bio to Announce Second Quarter 2026 Financial Results

May 12, 2026, 4:30 PM EDT - 3 months ago

TELA Bio Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

TELA Bio Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

TELA Bio Quarterly report: Q1 2026

May 12, 2026, 4:05 PM EDT - 3 months ago

TELA Bio Reports First Quarter 2026 Financial Results

Apr 30, 2026, 4:43 PM EDT - 3 months ago

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

Apr 30, 2026, 8:00 AM EDT - 3 months ago

TELA Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

TELA Bio Proxy statement: Proxy filing

Apr 21, 2026, 4:05 PM EDT - 4 months ago

TELA Bio to Announce First Quarter 2026 Financial Results

2026-03-27T09:45:34.000Z - 5 months ago

Tela Bio price target lowered to $3 from $5 at Citizens

2026-03-25T12:46:38.000Z - 5 months ago

Tela Bio price target lowered to $2 from $3 at Lake Street

2026-03-25T10:47:07.000Z - 5 months ago

Tela Bio price target lowered to $2 from $4 at Canaccord

2026-03-25T10:45:14.000Z - 5 months ago

Tela Bio price target lowered to $1 from $1.25 at Piper Sandler

Mar 24, 2026, 4:30 PM EDT - 5 months ago

TELA Bio Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

TELA Bio Annual report: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

TELA Bio Earnings release: Q4 2025

2026-03-24T20:18:38.000Z - 5 months ago

Tela Bio reports Q4 EPS (17c), consensus (18c)

2026-03-24T20:18:24.000Z - 5 months ago

Tela Bio sees Q1 revenue $18.5M, consensus $21.27M

Mar 24, 2026, 4:05 PM EDT - 5 months ago

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 10, 2026, 4:05 PM EDT - 5 months ago

TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results

2025-12-12T12:15:29.000Z - 8 months ago

Tela Bio files to sell 2M shares of common stock for holders

Dec 12, 2025, 7:00 AM EST - 8 months ago

TELA Bio Registration statement: Registration Filing

Dec 3, 2025, 2:30 PM EST - 9 months ago

TELA Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-01T13:45:43.000Z - 9 months ago

Tela Bio price target lowered to $3 from $6 at Lake Street

Nov 19, 2025, 8:30 AM EST - 9 months ago

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-11-18T11:15:46.000Z - 9 months ago

Tela Bio price target lowered to $4 from $7 at Canaccord

2025-11-14T11:51:53.000Z - 9 months ago

Tela Bio price target lowered to $1.25 from $2 at Piper Sandler

2025-11-14T10:55:56.000Z - 9 months ago

Tela Bio price target lowered to $5 from $7 at Citizens JMP

Nov 13, 2025, 4:30 PM EST - 9 months ago

TELA Bio Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

TELA Bio Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

TELA Bio Earnings release: Q3 2025

Nov 13, 2025, 4:21 PM EST - 9 months ago

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants

2025-11-13T21:17:42.000Z - 9 months ago

Tela Bio reports Q3 EPS (19c), consensus (20c)

2025-11-13T21:17:31.000Z - 9 months ago

Tela Bio sees FY25 revenue up at least 16%

Nov 13, 2025, 4:01 PM EST - 9 months ago

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility

Oct 9, 2025, 4:05 PM EDT - 11 months ago

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

Aug 13, 2025, 10:00 AM EDT - 1 year ago

TELA Bio Transcript: Canaccord Genuity’s 45th Annual Growth Conference

2025-08-11T20:30:41.000Z - 1 year ago

Tela Bio reports Q2 EPS (22c), consensus (19c)

2025-08-11T20:30:35.000Z - 1 year ago

Tela Bio backs FY25 revenue view $85M-$88M, consensus $86.05M

Aug 11, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings release: Q2 2025

Aug 11, 2025, 4:03 PM EDT - 1 year ago

TELA Bio Reports Second Quarter 2025 Financial Results

Aug 10, 2025, 6:00 PM EDT - 1 year ago

TELA Bio Slides: Investor Presentation

Jul 23, 2025, 4:03 PM EDT - 1 year ago

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 21, 2025, 4:03 PM EDT - 1 year ago

TELA Bio to Announce Second Quarter 2025 Financial Results

Jun 6, 2025, 4:05 PM EDT - 1 year ago

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2025, 11:05 AM EDT - 1 year ago

TELA Bio Transcript: Jefferies Global Healthcare Conference 2025

2025-06-03T20:50:13.000Z - 1 year ago

Tela Bio announces European launch of OviTex Inguinal Reinforced Tissue Matrix

Jun 3, 2025, 4:05 PM EDT - 1 year ago

TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

2025-06-02T12:40:54.000Z - 1 year ago

Tela Bio appoints Jeffrey Blizard as president, effective immediately

JNJ

Jun 2, 2025, 8:30 AM EDT - 1 year ago

TELA Bio Appoints Jeffrey Blizard as President

May 22, 2025, 4:05 PM EDT - 1 year ago

TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings release: Q1 2025

Apr 17, 2025, 4:05 PM EDT - 1 year ago

TELA Bio to Announce First Quarter 2025 Financial Results

Apr 17, 2025, 8:00 AM EDT - 1 year ago

TELA Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

TELA Bio Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

TELA Bio Proxy statement: Proxy Filing

Mar 20, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings Call Transcript: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Annual report: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings release: Q4 2024

Mar 20, 2025, 4:05 PM EDT - 1 year ago

TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results

Dec 3, 2024, 12:00 PM EST - 1 year ago

TELA Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 1 year ago

TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference

Nov 7, 2024, 4:30 PM EST - 1 year ago

TELA Bio Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

TELA Bio Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

TELA Bio Earnings release: Q3 2024

Oct 24, 2024, 4:05 PM EDT - 1 year ago

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 23, 2024, 8:07 AM EDT - 1 year ago

TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Oct 22, 2024, 4:05 PM EDT - 1 year ago

TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Oct 17, 2024, 4:05 PM EDT - 1 year ago

TELA Bio to Announce Third Quarter 2024 Financial Results

Aug 14, 2024, 10:30 AM EDT - 2 years ago

TELA Bio Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 12, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings release: Q2 2024

Aug 12, 2024, 4:05 PM EDT - 2 years ago

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance

Jul 22, 2024, 4:05 PM EDT - 2 years ago

TELA Bio to Announce Second Quarter 2024 Financial Results

Jun 4, 2024, 4:05 PM EDT - 2 years ago

TELA Bio Appoints Jeffrey Blizard to its Board of Directors

May 20, 2024, 4:03 PM EDT - 2 years ago

TELA Bio Appoints Greg Firestone as Chief Commercial Officer

May 9, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings release: Q1 2024

May 9, 2024, 4:05 PM EDT - 2 years ago

TELA Bio Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 2 years ago

TELA Bio to Announce First Quarter 2024 Financial Results

Apr 18, 2024, 8:00 AM EDT - 2 years ago

TELA Bio Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

TELA Bio Proxy statement: Proxy Filing

Apr 15, 2024, 7:00 AM EDT - 2 years ago

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

Apr 8, 2024, 7:00 AM EDT - 2 years ago

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

Mar 21, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings Call Transcript: Q4 2023

Mar 21, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Annual report: Q4 2023

Mar 21, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings release: Q4 2023

Mar 21, 2024, 4:05 PM EDT - 2 years ago

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

Mar 21, 2024, 7:00 AM EDT - 2 years ago

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

Mar 20, 2024, 7:00 AM EDT - 2 years ago

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX

Feb 29, 2024, 7:00 AM EST - 2 years ago

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results

Dec 5, 2023, 7:00 AM EST - 2 years ago

TELA Bio to Take Part in Connecting the Dots

Nov 30, 2023, 11:00 AM EST - 2 years ago

TELA Bio Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 16, 2023, 7:00 AM EST - 2 years ago

TELA Bio to Participate in Piper Sandler's 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 3 years ago

TELA Bio Registration statement: Registration Filing

Nov 9, 2023, 4:30 PM EST - 3 years ago

TELA Bio Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 3 years ago

TELA Bio Quarterly report: Q3 2023

Nov 9, 2023, 4:30 PM EST - 3 years ago

TELA Bio Earnings release: Q3 2023

Nov 9, 2023, 4:05 PM EST - 3 years ago

TELA Bio Reports Third Quarter 2023 Financial Results

Oct 26, 2023, 7:00 AM EDT - 3 years ago

TELA Bio to Announce Third Quarter 2023 Financial Results

Sep 18, 2023, 4:05 PM EDT - 3 years ago

TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

Aug 16, 2023, 7:00 AM EDT - 3 years ago

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Aug 9, 2023, 4:30 PM EDT - 3 years ago

TELA Bio Earnings Call Transcript: Q2 2023

Aug 9, 2023, 4:30 PM EDT - 3 years ago

TELA Bio Quarterly report: Q2 2023

Aug 9, 2023, 4:30 PM EDT - 3 years ago

TELA Bio Earnings release: Q2 2023

Aug 9, 2023, 4:03 PM EDT - 3 years ago

TELA Bio Reports Second Quarter 2023 Financial Results

Jul 26, 2023, 7:00 AM EDT - 3 years ago

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

Jun 15, 2023, 7:00 AM EDT - 3 years ago

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

May 25, 2023, 7:00 AM EDT - 3 years ago

TELA Bio to Participate in the Jefferies Global Healthcare Conference